Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

• Status: Withdrawn
• Trial end date: 2003-03-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation using specially treated stem cells may allow the doctor to give higher doses of chemotherapy drugs and radiation therapy and kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation using specially treated stem cells in treating patients who have non-Hodgkin's lymphoma or Hodgkin's disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Masonic Cancer Center, University of Minnesota
• Collaborator: National Cancer Institute (NCI)
• Treatments: Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Mitoxantrone

Criteria

DISEASE CHARACTERISTICS:

• Intermediate or high grade non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD)

• Chemotherapy sensitive, initial partial remission OR

• Relapse after initial complete or partial remission

• Low grade NHL eligible provided progression following initial partial or complete remission

• Ineligible for ongoing allogeneic marrow donor transplant protocols or elected not to participate in such protocols

• No chemotherapy resistant NHL or HD NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS:

Age:

• 18 to 70

Performance status:

• Karnofsky 90-100%

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• AST less than 2.5 times upper limit of normal (ULN)

• Bilirubin less than 2.5 times ULN

Renal:

• Creatinine less than 2.0 mg/dL

Cardiovascular:

• Resting LVEF at least 40%

• No unstable ischemic heart disease

Pulmonary:

• Spirometry and DLCO greater than 50% predicted

Other:

• No active uncontrolled infection

• HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• See Disease Characteristics

Chemotherapy:

• See Disease Characteristics

• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)

Endocrine therapy:

• Not specified

Radiotherapy:

• Not specified

Surgery:

• Not specified